Pr Judith V.M.G. Bovée, MD,PhD
2333 ZA Leiden
Postalzone L1-Q, P.O. Box 9600
2300 RC Leiden
Professor Judith V.M.G. Bovée is a clinician scientist at the Department of Pathology, LUMC, with a special focus on bone and soft tissue tumours. Her aim is to crosslink patient care (diagnostic pathology of bone and soft tissue tumours) with basic research (elucidating the molecular events underlying sarcoma development and progression) in order to establish improved diagnosis, prognosis and treatment for patients with bone and soft tissue tumours.
For my researchgroup: https://www.lumc.nl/org/pathologie/research/90708043159185/90708043344185/
- Work package leader in Eurosarc collaborative project; WP2 translational research (FP7)
- Reference pathologist EORTC Soft Tissue and Bone Sarcoma Group
- Work package leader in the Eurobonet Network of Excellence WP1.1 "Biology of central and peripheral chondrosarcoma" (FP6; till 2012)
- Board member of the European MusculoSkeletal Oncology Society (till 2012)
- Board member of the dutch working group for molecular diagnostics in pathology
- Member Netherlands Committee on Bone Tumours
- Member of scientific advisory board of Dutch Multiple Osteochondromas patient organization
- Senior editor International Journal of Clinical and Experimental Pathology
- Editor Clinical sarcoma research
- “ Epigenetic changes caused by IDH mutation as a target for novel anticancer therapy”. Dutch Cancer Society / Koningin Wilhelmina Fonds 2013-2017
PI: Bovée JVMG. Other projectleader: van de Water B.
- “Imaging Altered Metabolism in Cancer”. LUMC Profile area “Biomedical Imaging” 2013
PIs: J. Morreau, JVMG Bovée, L. McDonnell
- “A “bedside to bench” investigational platform for the study of myxoid liposarcoma”; Liddy Shriver Sarcoma Initiative 2012-2014
PI: T. Nielsen (Vancouver, Canada). Other projectleaders: JVMG Bovée, A. Lazar and D. Lev (Houston, USA).
- Participation in EuroSarc consortium. Seventh Framework, collaborative project, theme Health (“Investigator-driven treatment trials for rare cancers”) 2012-2017 Full title: “European Clinical trials in Rare Sarcomas within an integrated translational trial network”. Work-package leader WP2 “Molecular diagnosis and translational research” and member of executive committee. Coordinator: J.Y. Blay.
- “Identification and validation of novel kinase drug targets for sarcoma growth and therapy resistance”. Leiden University, Research Profile “Translational drug discovery and development”.
PI: Danen E. Other projectleaders: Bovée JVMG, van de Water B, Hogendoorn PCW
- “Reverting chemo- and radioresistance mechanisms in chondrosarcoma: targeting anti-apoptotic machinery components and pro-survival signaling pathways”
Dutch Cancer Society / Koningin Wilhelmina Fonds 2011-2015
PI: Bovée JVMG. Other projectleaders: van de Water B., Karperien M.
- Pansuriya TC, van Eijk R, d’ Adamo P, Kuijjer ML, van Ruler MAJH, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SLJ, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M , Kurek KC, Szuhai K, French PJ, Bovée JVMG. Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics 2011: 43(12);1256-61
- Bovée JVMG, Hogendoorn PCW, Wunder JS, Alman BA. Cartilage tumors and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010; 10(7):481-8
- Bovée JVMG. EXTra hit for mouse osteochondroma. Proc Natl Acad Science USA 2010: 107(5):1813-1814
- Schrage YM, Briaire-de Bruijn IH, de Miranda NFCC, van Oosterwijk J, Taminiau AHM, van Wezel T, Hogendoorn PCW, and Bovée JVMG. Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment. Cancer Res 2009: 69(15):6216-22
- Bovée JVMG, Cleton-Jansen AM, Taminiau AHM and Hogendoorn PCW. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005; 6: 599–607